Cargando…
Uliginosin B, a Possible New Analgesic Drug, Acts by Modulating the Adenosinergic System
Uliginosin B (ULI) is a natural acylphloroglucinol that has been proposed as a new molecular scaffold for developing analgesic and antidepressant drugs. Its effects seem to be due to its ability to increase monoamines in the synaptic cleft by inhibiting their neuronal uptake without binding to their...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819114/ https://www.ncbi.nlm.nih.gov/pubmed/27087824 http://dx.doi.org/10.1155/2016/5890590 |
_version_ | 1782425142992830464 |
---|---|
author | Stolz, Eveline Dischkaln da Costa, Paola Fontoura Medeiros, Liciane Fernandes Souza, Andressa Battastini, Ana Maria Oliveira von Poser, Gilsane Lino Bonan, Carla Torres, Iraci L. S. Rates, Stela Maris Kuze |
author_facet | Stolz, Eveline Dischkaln da Costa, Paola Fontoura Medeiros, Liciane Fernandes Souza, Andressa Battastini, Ana Maria Oliveira von Poser, Gilsane Lino Bonan, Carla Torres, Iraci L. S. Rates, Stela Maris Kuze |
author_sort | Stolz, Eveline Dischkaln |
collection | PubMed |
description | Uliginosin B (ULI) is a natural acylphloroglucinol that has been proposed as a new molecular scaffold for developing analgesic and antidepressant drugs. Its effects seem to be due to its ability to increase monoamines in the synaptic cleft by inhibiting their neuronal uptake without binding to their respective transporters, but its exact mode of action is still unknown. Considering the importance of the purinergic system to pain transmission and its modulation by monoamines availability, the aim of this study was to investigate the involvement of adenosinergic signaling in antinociceptive effect of uliginosin B. The selective adenosine A(1) receptor antagonist DPCPX and the selective A(2A) antagonist ZM 241385 prevented the effect of ULI in the hot-plate test in mice. Pretreatment with inhibitors of adenosine reuptake (dipyridamole) or adenosine deaminase (EHNA) did not affect the ULI effect. On the other hand, its effect was completely prevented by an inhibitor of ecto-5′-nucleotidase (AMPCP). This finding was confirmed ex vivo, whereby ULI treatment increased AMP and ATP hydrolysis in spinal cord and cerebral cortex synaptosomes, respectively. Altogether, these data indicate that activation of A(1) and A(2A) receptors and the modulation of ecto-5′-nucleotidase activity contribute to the antinociceptive effect of ULI. |
format | Online Article Text |
id | pubmed-4819114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-48191142016-04-17 Uliginosin B, a Possible New Analgesic Drug, Acts by Modulating the Adenosinergic System Stolz, Eveline Dischkaln da Costa, Paola Fontoura Medeiros, Liciane Fernandes Souza, Andressa Battastini, Ana Maria Oliveira von Poser, Gilsane Lino Bonan, Carla Torres, Iraci L. S. Rates, Stela Maris Kuze Evid Based Complement Alternat Med Research Article Uliginosin B (ULI) is a natural acylphloroglucinol that has been proposed as a new molecular scaffold for developing analgesic and antidepressant drugs. Its effects seem to be due to its ability to increase monoamines in the synaptic cleft by inhibiting their neuronal uptake without binding to their respective transporters, but its exact mode of action is still unknown. Considering the importance of the purinergic system to pain transmission and its modulation by monoamines availability, the aim of this study was to investigate the involvement of adenosinergic signaling in antinociceptive effect of uliginosin B. The selective adenosine A(1) receptor antagonist DPCPX and the selective A(2A) antagonist ZM 241385 prevented the effect of ULI in the hot-plate test in mice. Pretreatment with inhibitors of adenosine reuptake (dipyridamole) or adenosine deaminase (EHNA) did not affect the ULI effect. On the other hand, its effect was completely prevented by an inhibitor of ecto-5′-nucleotidase (AMPCP). This finding was confirmed ex vivo, whereby ULI treatment increased AMP and ATP hydrolysis in spinal cord and cerebral cortex synaptosomes, respectively. Altogether, these data indicate that activation of A(1) and A(2A) receptors and the modulation of ecto-5′-nucleotidase activity contribute to the antinociceptive effect of ULI. Hindawi Publishing Corporation 2016 2016-03-21 /pmc/articles/PMC4819114/ /pubmed/27087824 http://dx.doi.org/10.1155/2016/5890590 Text en Copyright © 2016 Eveline Dischkaln Stolz et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Stolz, Eveline Dischkaln da Costa, Paola Fontoura Medeiros, Liciane Fernandes Souza, Andressa Battastini, Ana Maria Oliveira von Poser, Gilsane Lino Bonan, Carla Torres, Iraci L. S. Rates, Stela Maris Kuze Uliginosin B, a Possible New Analgesic Drug, Acts by Modulating the Adenosinergic System |
title | Uliginosin B, a Possible New Analgesic Drug, Acts by Modulating the Adenosinergic System |
title_full | Uliginosin B, a Possible New Analgesic Drug, Acts by Modulating the Adenosinergic System |
title_fullStr | Uliginosin B, a Possible New Analgesic Drug, Acts by Modulating the Adenosinergic System |
title_full_unstemmed | Uliginosin B, a Possible New Analgesic Drug, Acts by Modulating the Adenosinergic System |
title_short | Uliginosin B, a Possible New Analgesic Drug, Acts by Modulating the Adenosinergic System |
title_sort | uliginosin b, a possible new analgesic drug, acts by modulating the adenosinergic system |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819114/ https://www.ncbi.nlm.nih.gov/pubmed/27087824 http://dx.doi.org/10.1155/2016/5890590 |
work_keys_str_mv | AT stolzevelinedischkaln uliginosinbapossiblenewanalgesicdrugactsbymodulatingtheadenosinergicsystem AT dacostapaolafontoura uliginosinbapossiblenewanalgesicdrugactsbymodulatingtheadenosinergicsystem AT medeiroslicianefernandes uliginosinbapossiblenewanalgesicdrugactsbymodulatingtheadenosinergicsystem AT souzaandressa uliginosinbapossiblenewanalgesicdrugactsbymodulatingtheadenosinergicsystem AT battastinianamariaoliveira uliginosinbapossiblenewanalgesicdrugactsbymodulatingtheadenosinergicsystem AT vonposergilsanelino uliginosinbapossiblenewanalgesicdrugactsbymodulatingtheadenosinergicsystem AT bonancarla uliginosinbapossiblenewanalgesicdrugactsbymodulatingtheadenosinergicsystem AT torresiracils uliginosinbapossiblenewanalgesicdrugactsbymodulatingtheadenosinergicsystem AT ratesstelamariskuze uliginosinbapossiblenewanalgesicdrugactsbymodulatingtheadenosinergicsystem |